Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective, Open, Single-center Clinical Study of the Combination of RC48 and Tislelizumab for Renal Preservation in High-risk Upper Urinary Tract Uroepithelial Carcinoma Patients

Next Previous
Trial Profile

Prospective, Open, Single-center Clinical Study of the Combination of RC48 and Tislelizumab for Renal Preservation in High-risk Upper Urinary Tract Uroepithelial Carcinoma Patients

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Disitamab vedotin (Primary) ; Tislelizumab (Primary)
  • Indications Bladder cancer; Urogenital cancer
  • Focus Therapeutic Use

Most Recent Events

  • 07 Jan 2025 The protocol has been amended.
  • 03 Dec 2024 Planned End Date changed from 10 Dec 2026 to 30 Dec 2026.
  • 03 Dec 2024 Planned primary completion date changed from 10 Dec 2025 to 30 Dec 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top